AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04638075 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Supplemental Nursing System
Description: The SNS is a device designed to deliver supplemental milk by suckling at the mother's nipple. A specially designed bottle attaches to the mother's breast and serves as the reservoir for milk. Attached to the bottle is a small tube which runs down to and is placed on the tip of the mother's nipple. With an adequate latch the neonate obtains supplementation by suckling. Additionally, this suckling stimulates milk production (Lawrence \& Lawrence, 2016).
Study NCT06486012 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lumoral Treatment
Description: Photodynamic antibacterial dual-light device home-use with a marker substance
Study NCT06486012 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard oral hygiene
Description: Standard oral hygiene performed at home
Study NCT06486012 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard oral hygiene
Description: Standard oral hygiene performed at home
Study NCT05014776 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tadalafil
Description: Patients will receive treatment every 3 weeks for 6 cycles of treatment within a course (total of 18 weeks). Tadalafil (20 mg) will be administered orally every day on days 3-21 for cycles 1-6.
Study NCT05014776 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Patients will receive treatment every 3 weeks for 6 cycles of treatment within a course (total of 18 weeks). Pembrolizumab (200 mg) will be administered IV on Day 1 of cycles 1-6.
Study NCT05014776 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Patients will receive treatment every 3 weeks for 6 cycles of treatment within a course (total of 18 weeks). Ipilimumab (50mg) will be administered IV on Day 1 of Cycles 1, 3, and 5.
Study NCT05014776 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CRS-207
Description: Patients will receive treatment every 3 weeks for 6 cycles of treatment within a course (total of 18 weeks). CRS-207 \[1 × 10\^9 colony forming units (CFU) in 100ml NS\] will be administered IV on Day 2 of Cycles 1-6.
Study NCT04354077 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DBS of the NAc
Description: Deep Brain Stimulation of the Nucleus Accumbens
Study NCT06565455 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: La CASA (Comunidad, Alimentación, Seguridad y Amén) Program: Healthy Eating Intervention
Description: The intervention will consist of seven healthy eating culturally developed modules, which will be implemented/delivered in the participants home and two cooking demonstration/tasting workshops for the participants in the intervention group (mothers in the church setting and individual and collective goal settings for the intervention group.
Study NCT04530565 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biospecimen Collection
Description: Correlative studies
Study NCT04530565 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Correlative studies
Study NCT04530565 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blinatumomab
Description: Given IV
Study NCT04530565 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bone Marrow Aspiration and Biopsy
Description: Undergo bone marrow aspiration and biopsy
Study NCT04530565 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Aspiration and Biopsy
Description: Undergo bone marrow aspiration and biopsy
Study NCT04530565 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV
Study NCT04530565 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given IV or IT
Study NCT04530565 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dasatinib
Description: Given PO
Study NCT04530565 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Description: Given PO
Study NCT04530565 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given PO or IV
Study NCT04530565 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin Hydrochloride
Description: Given IV
Study NCT04530565 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Echocardiography
Description: Undergo ECHO
Study NCT04530565 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Echocardiography
Description: Undergo ECHO
Study NCT04530565 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Electrocardiography
Description: Undergo ECG
Study NCT04530565 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Electrocardiography
Description: Undergo ECG
Study NCT04530565 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Lumbar Puncture
Description: Undergo lumbar puncture
Study NCT04530565 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lumbar Puncture
Description: Undergo lumbar puncture
Study NCT04530565 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesna
Description: Given IV
Study NCT04530565 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Given IV or IT
Study NCT04530565 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Multigated Acquisition Scan
Description: Undergo MUGA
Study NCT04530565 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Multigated Acquisition Scan
Description: Undergo MUGA
Study NCT04530565 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ponatinib Hydrochloride
Description: Given PO
Study NCT04530565 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ponatinib Hydrochloride
Description: Given PO
Study NCT04530565 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: Given PO
Study NCT04530565 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine Sulfate
Description: Given IV
Study NCT05735834 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Truxima concentrate for solution for infusion 500 mg/50 ml
Study NCT06174597 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: UCA-PSCs/bFGF or bFGF Intramuscular injection
Description: After skin disinfection, according to the distribution characteristics of blood vessels around the vascular lesion area, the site that is most likely to establish a new collateral circulation in vascular anatomy is selected. According to the vascular lesion of each subject, 40 reasonable injection sites are selected for Clusters of umbilical cord artery-derived perivascular stem cells with bFGF or bFGF only.
Study NCT06174597 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: UCA-PSCs/bFGF or bFGF Intramuscular injection
Description: After skin disinfection, according to the distribution characteristics of blood vessels around the vascular lesion area, the site that is most likely to establish a new collateral circulation in vascular anatomy is selected. According to the vascular lesion of each subject, 40 reasonable injection sites are selected for Clusters of umbilical cord artery-derived perivascular stem cells with bFGF or bFGF only.
Study NCT05735834 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: Truxima concentrate for solution for infusion 500 mg/50 ml
Study NCT05735834 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zanubrutinib
Description: Zanubrutinib 80 mg hard capsules
Study NCT06245408 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dazodalibep
Description: IV infusion
Study NCT06245408 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: IV infusion
Study NCT05719558 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP1002
Description: intravenous (IV) infusion
Study NCT05889182 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Upadacitinib
Description: Oral Tablets
Study NCT05889182 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral Tablets
Study NCT05889182 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral Tablets
Study NCT06226883 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo (identical appearance to MORF-057) administered orally.
Study NCT06226883 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MORF-057
Description: MORF-057 is a small molecule that is designed to selectively inhibit integrin α4β7 and is administered orally.
Study NCT06226883 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: MORF-057
Description: MORF-057 is a small molecule that is designed to selectively inhibit integrin α4β7 and is administered orally.
Study NCT05946941 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deucravacitinib
Description: Specified dose on specified days
Study NCT05946941 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Deucravacitinib
Description: Specified dose on specified days
Study NCT05946941 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Specified dose on specified days
Study NCT06422806 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection
Study NCT06422806 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biospecimen Collection
Description: Undergo blood sample collection
Study NCT06422806 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Diagnostic Imaging
Description: Undergo standard imaging scans
Study NCT06422806 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Diagnostic Imaging
Description: Undergo standard imaging scans
Study NCT06422806 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Given IV
Study NCT06422806 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin
Description: Given IV
Study NCT06422806 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Echocardiography
Description: Undergo ECHO
Study NCT06422806 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Echocardiography
Description: Undergo ECHO
Study NCT06428942 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: low-potassium vegetables
Description: low-potassium vegetables 3 to 5 serving according to their daily suggested requirement
Study NCT06422806 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Multigated Acquisition Scan
Description: Undergo MUGA scan
Study NCT06422806 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Multigated Acquisition Scan
Description: Undergo MUGA scan
Study NCT06422806 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV
Study NCT05439993 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tepotinib plus paclitaxel
Description: Paclitaxel 80mg/m2 on D1, 8, 15 tepotinib 250mg or 500mg daily on D1-28 Q 4weeks
Study NCT06569121 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group Lifestyle Balance for People Post Stroke (GLB-CVA)
Description: 12-month healthy lifestyle and weight loss program modified from the Diabetes Prevention Program Group Lifestyle Balance (DPP-GLB)
Study NCT05754437 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low Level Light Therapy
Description: light-emitting diodes (LED), λ = 633 ± 10 nm; power of 100 mW/cm2, 15 minutes
Study NCT06465563 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-8068
Description: SHR-8068
Study NCT06465563 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adebrelimab
Description: Adebrelimab
Study NCT06465563 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin
Study NCT06465563 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine
Study NCT05836324 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCA33890
Description: INCA33890 will be administered at protocol defined dose.
Study NCT05698017 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: hOMSC300
Description: Human Oral Mucosa Stem Cells
Study NCT06404489 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multimodal prehabilitation Program
Description: A tailored intervention will be prescribed if specific physical, nutritional or psychological impairments will be identified during the assessment phase. Based on the data obtained during the multimodal assessment, different domains and levels of care will be prescribed, focusing on exercise training, and/or nutrition optimization, and/or distress-coping techniques. Different combinations of three domains will be utilized to maximize their synergistic anabolic effect.~The duration of program will be set at 4 weeks. All activities will be performed in dedicated suites at each site, under supervision of qualified health professionals.
Study NCT05209594 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healthy Relationships Program (HRP) for 2SLGBTQIA+ Youth
Description: The Healthy Relationships Program (HRP) for Two-Spirit, Lesbian, Gay, Bisexual, Trans, Queer, Intersex, and Asexual + (2SLGBTQIA+) Youth is a small group positive mental health promotion program for gender, sexual, and romantic minority youth. It helps build resiliency and promote well-being among 2SLGBTQIA+ youth. It affirms, validates, and celebrates sexual and gender diversity, cultivates a caring and supportive community, and helps 2SLGBTQIA+ youth develop skills and strategies that promote healthy relationships. This trauma-informed, strengths-focused program explores stressors unique to 2SLGBTQIA+ youth, including identity and expression invalidation, stigma, prejudice and discrimination, internalized oppression, coming out, safety, and microaggressions. This program includes 17 sessions, each lasting approximately 45 minutes. It may be delivered in school-based Genders and Sexualities Alliances/Gay-Straight Alliances (GSA) or 2SLGBTQIA+ youth group settings.
Study NCT05209594 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard GSA Programming
Description: Students at comparison sites will participate in standard GSA programming, a safe space for 2SLGBTQIA+ youth and their allies to meet, develop relationships, support each other, socialize, and learn about sexuality and gender-related topics, and lobby for social change.
Study NCT04864314 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Marine microalgae Tetraselmis chuii with high Superoxide Dismutase (SOD) activity
Description: Participants in the Experimental group will receive a daily dose of 250 mg of TetraSOD® in a capsule during 90 days. After treatment, the group will stop consumption of TetraSOD® and a wash-out period of three months will start
Study NCT04864314 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Sham
Description: Participants in the Control group will receive a daily dose of placebo in a capsule during 90 days. After treatment, the group will stop consumption of placebo and a wash-out period of three months will start
Study NCT06477965 — intervention group
Intervention type: PROCEDURE
Intervention: Artery Embolization
Description: Embolic Solution are intended for use in occluding blood vessels for therapeutic or operative purposes. The embolic solution is used during an outpatient procedure, the physician will insert a small catheter onto the artery supplying the lining of the target joint or target localized pain. Tiny particles are then injected through the catheter into these arteries, reducing blood flow to the target area. This reduces the amount of inflammation associated with osteoarthritis, tendonitis, tenosynovitis or an injury, a process that can help decrease symptoms or eliminate the associated localized pain to this area. With understanding that it does not treat the underlying cartilage destruction or underlying condition causing pain but would like to determine the efficacy and validity of this treatment.
Study NCT04860505 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxycycline
Description: Doxycycline (DOX \[200 mg\]) is an oral medication used to treat or prevent infections that are strongly suspected to be caused by bacteria; it is an antimicrobial drug indicated for bacterial infections such as sexually transmitted infections.
Study NCT04860505 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Biktarvy
Description: Biktarvy (200mg) is an oral combination anti-HIV medication that contains the drugs tenofovir alafenamide, emtricitabine, and bictegravir.
Study NCT06226155 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TENDAI4PrEP
Description: An adapted problem-solving PrEP use intervention for HIV negative pregnant persons living with psychological distress, their partners, and antenatal care providers.
Study NCT06226155 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced treatment as usual
Description: Includes monthly visits to the ANC plus a pamphlet of information that describes PrEP efficacy.~safety during pregnancy/postpartum, and PrEP availability at the ANC.
Study NCT04780074 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Single dose intervention with Standard product (SP)
Description: 2 capsules - 200 mg total CoQ10
Study NCT04780074 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Single dose intervention with Investigational product (IP1)
Description: 2 softgels - 200 mg total CoQ10
Study NCT04780074 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Single dose intervention with Investigational product (IP2)
Description: 2 softgels - 200 mg total CoQ10
Study NCT04780074 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Single dose intervention with Investigational product (IP3)
Description: 2 softgels - 200 mg total CoQ10
Study NCT04780074 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Single dose intervention with Investigational product (IP4)
Description: 2 capsules - 200 mg total CoQ10
Study NCT04826406 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab combined Apatinib regimen
Description: Camrelizumab 200mg iv every 2 weeks; Apatinib,250 mg/day.
Study NCT05240794 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ABM-01
Description: Gamified computerized behavioral therapy with therapeutic intervention based on Attention Bias Modification Training (ABMT)
Study NCT05240794 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Digital Control
Description: Placebo control for ABM-01
Study NCT06303674 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical activity with engaging cognitively
Description: This experimental condition will follow the following structure: involving 10 consecutive, 30 second-blocks of physical activity. This experimental condition will focus on aerobic metabolism. The total exercise time commitment is 10 minutes (30 seconds of working - 30 seconds of executing an engaging cognitive task, 1:1 work-to-rest ratio), plus 5 minutes of warm-ups and 5 minutes of cool-down activities. The cognitive task consists of solving various tangrams.
Study NCT06303674 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical activity without engaging cognitively
Description: This experimental condition will replicate the structure of the preceding one. Participants will engage in physical activity, guided by video observation and imitation. However, during the rest periods, they will refrain from engaging in cognitive tasks
Study NCT06504901 — intervention group
Intervention type: DRUG
Intervention: Tislelizumab
Description: Tislelizumab 200mg ivd D1
Study NCT06504901 — intervention group
Intervention type: DRUG
Intervention: Interleukin-2
Description: Interleukin 2 100IU HD,QOD d1-d14
Study NCT06504901 — intervention group
Intervention type: DRUG
Intervention: Capecitabine
Description: Capecitabine: 1000mg/m2 bid po, d1-d14
Study NCT06504901 — intervention group
Intervention type: DRUG
Intervention: Oxaliplatin
Description: Oxaliplatin 130mg/m2 ivd, d1
Study NCT05497115 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Trauma Resilience and Recovery Program
Description: The Trauma Resilience and Recovery Program is a stepped model of care that is designed to deliver education at the bedside about mental health recovery after traumatic injury as well as risk assessment and brief intervention for high-risk patients (Step 1), foster symptom self-monitoring and continued education (Step 2), screen for PTSD and depression 30 days post-injury (Step 3), and provide a referral and warm handoff to mental health services if needed (Step 4).
Study NCT06510569 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: U lab aligners
Description: Aligner group change the aligner every 10 days
Study NCT06510569 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: oramco bracket
Description: changing orthodontic wire every one month
Study NCT04754191 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enfortumab vedotin
Description: Cohort A will be treated with enfortumab vedotin on a 28 day cycle for up to 12 months.